Alectinib

An analysis of global online conversations among health care professionals on social media in April revealed tremendous enthusiasm about FDA approval of a treatment for adults with advanced HER2-positive solid tumors.

The FDA approved alectinib as an adjuvant treatment for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer following tumor resection and detection by an FDA-approved test.

MADRID — Hossein Borghaei, DO, MS, discussed results from the ALINA study on ALK-positive non-small cell lung cancer, which were presented at ESMO Congress, in a video interview with Healio.

MADRID — Alectinib significantly improved DFS compared with chemotherapy alone in patients with resected ALK-positive non-small cell lung cancer, according to research presented at ESMO Congress 2023.

MADRID — In a video interview, Julia Rotow, MD, discussed positive data from the ALINA study in ALK-positive non-small cell lung cancer presented at ESMO Congress.

Adjuvant therapy with alectinib prolonged DFS compared with platinum-based chemotherapy for certain patients with lung cancer, according to the agent’s manufacturer.

Today is World Lung Cancer Day.

Alectinib appeared less effective among patients with lung cancer when taken with low-fat yogurt compared with a fuller breakfast or lunch, according to data published in Journal of the National Comprehensive Cancer Network.

CHICAGO — Retrospective data showed how common central nervous system metastases are among patients with non-small cell lung cancer and ALK or ROS1 alterations who have been treated with tyrosine kinase inhibitors.